Sunday's Late-Breaking Science presentations
8-9 a.m. EST
LBS.03 | Prevention to Intervention in Atrial Arrhythmias
• The Coffee and Real-time Atrial and Ventricular Ectopy (CRAVE) Trial (CRAVE)
• Dabigatran Versus Warfarin on Cognitive Outcomes in Nonvalvular Atrial Fibrillation: Results of The GIRAF Trial. (GIRAF)
• Posterior Left Pericardiotomy Reduces Postoperative Atrial Fibrillation After Cardiac Surgery (PALACS)
• Outcomes of Adjunctive Left Atrial
Appendage Ligation Utilizing the LARIAT Compared to Pulmonary Vein Antral Isolation Alone: The AMAZE Trial (AMAZE)
2:45 pm - 3:45 p.m. EST
LBS.04 | Information Overload? Striving to Improve Care Delivery Through Digital Health and Automated Data
• Risk Evaluation and its Impact on Clinical Decision Making and Outcomes in Heart Failure: The REVeAL-HF Trial (REVeAL-HF)
• Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study
• Testing Individualized Triggers of Atrial Fibrillation: A Randomized Controlled Trial (I-STOP-AFib)
4-5 p.m. EST
LBS.05 | Building on the Foundations of Treatment: Advances in Heart Failure Therapy
• Empagliflozin in Heart Failure With a Preserved Ejection Fraction ≥50% - Results From the EMPEROR-Preserved Clinical Trial (EMPEROR-Preserved)
• The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Clinical Trial (CHIEF-HF)
• Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results From the EMPULSE Trial (EMPULSE)
• Randomized Trial of Targeted Transendocardial Delivery of Mesenchymal Precursor Cells in High-Risk Chronic Heart Failure Patients With
Reduced Ejection Fraction (DREAM-HF)
